Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Relugolix. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 14/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Relugolix SCHEMBL29386968 | 1.00 | GNRHR (1.00) | GNRHRKCNH2 | |
| SCHEMBL20742023 | 0.95 | GNRHR (1.00) | GNRHRKCNH2 | |
| SCHEMBL30461565 | 0.95 | GNRHR (1.00) | GNRHRKCNH2 | |
| SCHEMBL28979562 | 0.95 | GNRHR (1.00) | GNRHRKCNH2 | |
| SCHEMBL25007361 | 0.94 | GNRHR (0.89) | GNRHRKCNH2 | |
| SCHEMBL30461683 | 0.94 | GNRHR (0.89) | GNRHRKCNH2 | |
| SCHEMBL28979561 | 0.94 | GNRHR (0.89) | GNRHRKCNH2 | |
| SCHEMBL26756087 | 0.94 | GNRHR (0.88) | GNRHRKCNH2 | |
| SCHEMBL26476412 | 0.94 | GNRHR (1.00) | GNRHRKCNH2 | |
| SCHEMBL25421918 | 0.94 | GNRHR (0.88) | GNRHRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743069-A1 | STABLE SOLID DISPERSIONS OF SALCAPROZATE WITH VARIOUS ACTIVE PHARMACEUTICAL INGREDIENTS | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2026-05-20 | — | — | EP | claimed |
| US-12629370-B2 | Treatment of prostate cancer | Sumitomo Pharma Co., Ltd. (JP) | 2026-05-19 | — | — | US | claimed |
| WO-2026088112-A1 | COMBINATION THERAPIES WITH AR-DEGRADING AGENTS AND PSMA-TARGETING RADIOLIGANDS | NOVARTIS AG (CH) | 2026-04-30 | — | — | WO | claimed |
| EP-4727596-A2 | ANTIBODY-DRUG CONJUGATES AND LINKERS AND METHODS OF USE THEREOF | Ohio State Innovation Foundation (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260096905-A1 | IMPLANTABLE DRUG-DEVICE COMBINATIONS, AND RELATED METHODS OF TREATMENT | PITUVIA THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-4719422-A1 | PROGESTOGEN-FREE ORAL DOSAGE UNIT FOR USE IN FEMALE CONTRACEPTION AND TREATMENT OF ENDOMETRIOSIS | Pandora Endocrine Innovation B.V. (NL) | 2026-04-08 | — | — | EP | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4525938-B1 | RADIOPHARMACEUTICAL COMPLEXES TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND ITS COMBINATIONS | BAYER AG (DE) | 2026-03-11 | — | — | EP | claimed |
| US-12551447-B2 | Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists | Sumitomo Pharma Co., Ltd. (JP) | 2026-02-17 | — | — | US | claimed |
| US-9346822-B2 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-24 | — | — | US | claimed |
| US-20150266891-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | claimed |
| EP-1917978-B1 | Premature ovulation preventive agent | TAKEDA PHARMACEUTICAL (JP) | 2014-08-20 | — | — | EP | claimed |
| US-8735401-B2 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-27 | — | — | US | claimed |
| EP-1591446-B1 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2013-03-06 | — | — | EP | claimed |
| US-20110172249-A1 | METHOD FOR IMPROVING ABSORBABILITY OF PREPARATION, AND PREPARATION HAVING IMPROVED ABSORBABILITY | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2011-07-14 | — | — | US | claimed |
| EP-2329823-A1 | METHOD FOR IMPROVING ABSORBABILITY OF PREPARATION, AND PREPARATION HAVING IMPROVED ABSORBABILITY | Takeda Pharmaceutical Company Limited (JP) | 2011-06-08 | — | — | EP | claimed |
| US-7300935-B2 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-11-27 | — | — | US | claimed |
| US-20060160829-A1 | N-(4-(1-(2,6-difluorobenzyl)-5(((2-methoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea; gonadotropin releasing hormone (GnRH) antagonist; sex hormone dependent disease, antitumor agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-20 | — | — | US | claimed |
| EP-1591446-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2005-11-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160829-A1 | N-(4-(1-(2,6-difluorobenzyl)-5(((2-methoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea; gonadotropin releasing hormone (GnRH) antagonist; sex hormone dependent disease, antitumor agent | GNRHR, KISS1R, FSHR | GNRHR 1/4885KCNH2 588/4885 |
| US-12551447-B2 | Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists | PGRMC1, GNRHR, PGRMC2 | GNRHR 2/4885KCNH2 2332/4885 |
| US-20260096905-A1 | IMPLANTABLE DRUG-DEVICE COMBINATIONS, AND RELATED METHODS OF TREATMENT | PRLHR, GNRHR, LPXN | GNRHR 2/4885KCNH2 2631/4885 |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | CD4, TAP1, MCTS1 | GNRHR 2707/4885KCNH2 3111/4885 |
| US-20150266891-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | GNRHR, KISS1R, NR5A1 | GNRHR 1/4885KCNH2 1246/4885 |
| US-12629370-B2 | Treatment of prostate cancer | KLK3, DUT, DPYD | GNRHR 737/4885KCNH2 3505/4885 |
| US-20110172249-A1 | METHOD FOR IMPROVING ABSORBABILITY OF PREPARATION, AND PREPARATION HAVING IMPROVED ABSORBABILITY | SI, SLC10A2, FABP2 | GNRHR 2704/4885KCNH2 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.